A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
Titel:
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
Auteur:
O’Shaughnessy, Joyce DeMichele, Angela Ma, Cynthia X. Richards, Paul Yardley, Denise A. Wright, Gail Shaw Kalinsky, Kevin Steis, Ronald Diab, Sami Kennealey, Gerard Geschwindt, Ryan Jiang, Wei Rugo, Hope S.